Company / Cash & Equivalents
Medtronic Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.2B
FY2025
5-year range
$1.3B / $3.7B
FY2021-FY2025
Trend
+72.7%
vs FY2024
Sector context
#19 of 148
Health Care
What the data says
Medtronic's cash & equivalents of $2.2B is higher than 87% of companies in the Health Care sector (FY2025). Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $2.2B.
Based on SEC 10-K filings.
$2.2B in FY2025 with a 5-year CAGR of -11.7%. Top quartile in the Health Care sector.
Improved from $1.5B to $2.2B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -15.8%
- 5-Year CAGR
- -11.7%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 148This company $2.2B Sector average $1.2B
▼
+88.5% above sector average
Key checks
Key Insights
- 5-year CAGR of -11.7%, indicating a declining trend.
- In FY2025, cash & equivalents increased 72.7% year-over-year.
- Ranks #19 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2017.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | - | - |
| FY2025 | $2.2B | +72.7% |
| FY2024 | $1.3B | -16.8% |
| FY2023 | $1.5B | -58.5% |
| FY2022 | $3.7B | +3.4% |
| FY2021 | $3.6B | -13.2% |
| FY2020 | $4.1B | -5.8% |
| FY2019 | $4.4B | +19.7% |
| FY2018 | $3.7B | -26.1% |
| FY2017 | $5.0B | +72.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026